Navigation Links
Watson Reaches Settlement with Teva Over Seasonale(R)
Date:5/7/2010

MORRISTOWN, N.J., May 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the District of New Jersey involving Watson's Quasense® product, which is a generic equivalent of Teva's Seasonale®.  Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the U.S. patents covering Seasonale® and Watson will continue marketing its generic equivalent product Quasense® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg).  Watson further admits that the licensed patents are valid and enforceable.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance.  Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report for the year ended December 31,2009.  Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms EVISTA(R) Patent Challenge
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
3. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
4. Watson Confirms Trilipix(R) Patent Challenge
5. Watson Confirms Rapamune(R) Patent Challenge
6. Watson Confirms Cenestin(R) Patent Challenge
7. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
8. Watson to Present at Barclays 2010 Global Healthcare Conference
9. Watson Receives FDA Approval for Generic Cardizem(R) LA
10. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
11. Watson Announces Actos(R) Patent Challenge Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... February 23, 2017 Obese people ... caseload for varicose veins in their body. The rising ... prompting the adoption of endovenous laser therapy for treatment ... endovenous laser therapy market, published by Future Market ... choices and consequences of obesity have collectively factored the ...
(Date:2/23/2017)... February 23, 2017 The fast-growing cannabis ... the United States . According to the 2017 Legal ... is expected to create 283,422 jobs by 2020, with an ... the next four years. The accelerating pace of cannabis legalization ... of legal cannabis market, which will further create more business ...
(Date:2/23/2017)... February 23, 2017 The top ... are GE Healthcare, Koninklijke Philips N.V., and Schiller. Collectively, ... the global market in 2015. Strong product portfolio and ... assessed to be aiding these players remain leaders in ... the players in the global market are likely to ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... Justice jointly issued a letter to withdraw previous guidance issued by ... gender identity. The guidance issued in May 2016 by the Obama Administration came ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, ... June: From Not to Hot,” which will begin airing on February 24, 2017. The ... millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier ...
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at ... Top Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... dentists who have earned high ratings and superior patient reviews from multiple credible sources. ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center ... Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present ... spectrum disorder (ASD) to see films in an environment that accommodates their unique ...
(Date:2/23/2017)... ... ... HealthPostures, the desk for standing designer headquartered in Prior Lake, Minnesota has announced ... and Garden Show which is being held February 24 through 26 and March 3 ... Convention Center. , From its broad line of sit stand desk solutions, HealthPostures ...
Breaking Medicine News(10 mins):